|Articles|August 19, 2019

ASRS 2019 Street Team: Raj K. Maturi, MD

ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process

Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.

Newsletter

Don’t miss out—get Modern Retina updates delivered straight to your inbox.

Subscribe

Related Content

AMD lookback: Highlights from June 2026

ByKassi Filkins

July 10th 2026

Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

ByModern Retina Staff

June 30th 2026

Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 year

ByArshad M. Khanani, MD, MA, FASRS

June 29th 2026

Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence

ByCyrus Karkaria, PhD,Lucia Gambuzza

June 15th 2026

FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes

ByCyrus Karkaria, PhD,Modern Retina Staff

Published: June 5th 2026 | Updated: June 11th 2026

Latest CME

Video

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

Video

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Video

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

ASRS 2019 Street Team: Raj K. Maturi, MD

Related Content

AMD lookback: Highlights from June 2026

Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 year

Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence

FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Treatment Optimization in the Evolving Anti-VEGF Era

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD